Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 3749-3767

  Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; CARAZOLOL; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CVX 15; FLUORESCENT DYE; G PROTEIN COUPLED RECEPTOR; LIGAND; LJ 1251; MEMBRANE PROTEIN; ML 056; NANOCONJUGATE; NANOPARTICLE; NUCLEOTIDE; PURINERGIC P2Y RECEPTOR; RETINAL; RHODOPSIN; SPHINGOSINE DERIVATIVE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UK 432097; UK 532097; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SCREENING; HUMAN; HYDROPHILICITY; IN VIVO STUDY; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOLECULAR MODEL; MOLECULAR PROBE; MOLECULAR RECOGNITION; MOLECULE; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PROTEIN BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; DRUG DESIGN; DRUG DISCOVERY; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDICATORS AND REAGENTS; LIGANDS; NANOCONJUGATES; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A2A; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PURINERGIC P1; RECEPTORS, PURINERGIC P2Y; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84878088121     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400422s     Document Type: Review

References (127)

1. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Linden, J.; Müller, C. Nomenclature and classification of adenosine receptors-an update Pharmacol. Rev. 2011, 63, 1-34
2. Abbracchio, M. P.; Burnstock, G.; Boeynaems, J. M.; Barnard, E. A.; Boyer, J. L.; Kennedy, C.; Fumagalli, M.; King, B. F.; Gachet, C.; Jacobson, K. A.; Weisman, G. A. International Union of Pharmacology LVIII. Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy Pharmacol. Rev. 2006, 58, 281-341
3. Abbracchio, M. P.; Burnstock, G.; Verkhratsky, A.; Zimmermann, H. Purinergic signalling in the nervous system: an overview Trends Neurosci. 2008, 32, 19-29
4. Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets Nat. Rev. Drug Discovery 2006, 5, 247-264
5. Press, N. J.; Fozard, J. R. Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature Expert Opin. Ther. Pat. 2010, 20, 987-1005
6. von Kügelgen, I.; Harden, T. K. Molecular pharmacology, physiology, and structure of the P2Y receptors Adv. Pharmacol. 2011, 61, 373-415
7. Oh, Y. E.; Abraham, T.; Saad, N.; Rapp, J. H.; Vastey, F. L.; Balmir, E. A comprehensive comparative review of adenosine diphosphate receptor antagonists Expert Opin. Pharmacother. 2012, 13, 175-191
8. Vaidya, A.; Agarwal, A.; Jain, A.; Agrawal, R. K.; Jain, S. K. Bioconjugation of polymers: a novel platform for targeted drug delivery Curr. Pharm. Des. 2011, 17, 1108-1125
9. 2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis Sci. Transl. Med. 2012, 4, 146ra108
10. Jacobson, K. A.; Gao, Z. G.; Göblyös, A.; IJzerman, A. P. Allosteric modulators of purine and pyrimidine receptors Adv. Pharmacol. 2011, 61, 187-221
11. 3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers Biochem. Pharmacol. 2011, 82, 658-668
12. Reiter, E.; Ahn, S.; Shukla, A. K.; Lefkowitz, R. J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 179-197
13. 2A receptor Expert Rev. Clin. Pharmacol. 2010, 3, 55-72
14. Chen, J. F.; Eltzschig, H. K.; Fredholm, B. B. Adenosine receptors as drug targets-What are the challenges? Nat. Rev. Drug Discovery 2013, 12, 265-286
15. Jacobson, K. A.; Costanzi, S. New insights for drug design from the X-ray crystallographic structures of GPCRs Mol. Pharmacol. 2012, 82, 361-371
16. Dale, N.; Frenguelli, B. G. Release of adenosine and ATP during ischemia and epilepsy Curr. Neuropharmacol. 2009, 7, 160-179
17. Longhi, M. S.; Robson, S. C.; Bernstein, S. H.; Serra, S.; Deaglio, S. Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states J. Mol. Med. 2013, 91, 165-172
18. 3 receptors on mast cells J. Clin. Invest. 2000, 105, 361-367
19. Sitkovsky, M. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response Trends Immunol. 2009, 30, 102-108
20. 2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
21. 2A adenosine receptor Science 2011, 332, 322-327
22. 2A receptor Med. Chem. Commun. 2013, 4, 52-67
23. Topiol, S. X-ray structural information of GPCRs in drug design: What are the limitations and where do we go? Expert Opin. Drug Discovery [Online early access]. DOI: 10.1517/17460441.2013.783815. Published Online: Mar 29, 2013; http://informahealthcare.com/doi/abs/10.1517/17460441.2013.783815.
24. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293
25. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; IJzerman, A. P.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions Science 2012, 337, 232-236
26. 2A adenosine receptor J. Med. Chem. 2012, 55, 538-552
27. 3 adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions J. Med. Chem. 2012, 55, 4847-4860
28. 1 adenosine receptor antagonists PLoS One 2012, 7, e49910
29. Valant, C.; Lane, J. R.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178
30. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in pursuit of therapeutic adenosine receptor antagonists Med. Res. Rev. 2006, 26, 131-159
31. 3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary J. Med. Chem. 2002, 45, 4471-4484
32. Riksen, N. P.; Rongen, G. A. Targeting adenosine receptors in the development of cardiovascular therapeutics Expert Rev. Clin. Pharmacol. 2012, 5, 199-218
33. Gessi, S.; Merighi, S.; Fazzi, D.; Stefanelli, A.; Varani, K.; Borea, P. A. Adenosine receptor targeting in health and disease Expert Opin. Invest. Drugs 2011, 20, 1591-1609
34. 3AR) agonists Drug Discovery Today 2012, 17, 359-366
35. 3 adenosine receptor: An enigmatic player in cell biology Pharmacol. Ther. 2008, 117, 123-140
36. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
37. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models of structure-function relations in G protein-coupled receptors Methods Neurosci. 1995, 25, 366-428
38. 2A receptor antagonist, is active in primate models of movement disorders Exp. Neurol. 2010, 225, 384-390
39. Jacobson, K. A. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs) Bioconjugate Chem. 2009, 20, 1816-1835
40. 1 receptor Drug Des. Discovery 1992, 9, 49-67
41. 3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches Med. Res. Rev. 2013, 33, 235-335
42. 2a adenosine receptor J. Biol. Chem. 1995, 270, 13987-13997
43. Jacobson, K. A.; Costanzi, S.; Deflorian, F. Probing GPCR structure: adenosine and P2Y nucleotide receptors Methods Enzymol. 2013, 520, 199-217
44. 2A adenosine receptor and its agonists Chem. Biol. 2005, 12, 237-247
45. Conklin, B. R.; Hsiao, E. C.; Claeysen, S.; Dumuis, A.; Srinivasan, S.; Forsayeth, J. R.; Guettier, J. M.; Chang, W. C.; Pei, Y.; McCarthy, K. D.; Nissenson, R. A.; Wess, J.; Bockaert, J.; Roth, B. L. Engineering GPCR signaling pathways with RASSLs Nat. Methods 2008, 5, 673-678
46. 2A receptor structures reveal common features of GPCR activation Nature 2011, 474, 521-525
47. 1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo J. Pharmacol. Exp. Ther. 2009, 328, 306-311
48. 2A adenosine receptor crystallographic structure J. Med. Chem. 2009, 52, 3284-3292
49. 2A addeonsine receptors Life Sci. 1996, 59, 1373-1388
50. 2A receptor define ligand efficacy Mol. Pharmacol. 2013, 83, 949-958
51. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of opsin in its G-protein-interacting conformation Nature 2008, 455, 497-502
52. Rasmussen, S. G. F.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T. A.; Lyons, J. A.; Caffrey, M.; Gellman, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunihara, R. K.; Kobilka, B. K. Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 2011, 477, 549-555
53. 3 adenosine receptor-selective antagonists Neuropharmacology 1997, 36, 1157-1165
54. 2A receptor ligands J. Med. Chem. 2010, 53, 3748-3755
55. 3 adenosine receptor antagonists J. Med. Chem. 2008, 51, 6609-6613
56. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure Curr. Eye Res. 2005, 30, 747-754
57. 2A receptor J. Med. Chem. 2011, 54, 4312-4323
58. 2A receptor antagonists J. Med. Chem. 2010, 53, 1799-1809
59. 3 receptor antagonists J. Comput.-Aided Mol. Des. 2012, 26, 1247-1266
60. 2A receptor ligands ChemMedChem 2011, 6, 2302-2311
61. van Westen, G. J.; van den Hoven, O. O.; van der Pijl, R.; Mulder-Krieger, T.; de Vries, H.; Wegner, J. K.; IJzerman, A. P.; van Vlijmen, H. W.; Bender, A. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data J. Med. Chem. 2012, 55, 7010-7020
62. 2A receptor antagonists by virtual screening J. Med. Chem. 2012, 55, 1904-1909
63. 2A receptor with novel biological activity ACS Chem. Biol. 2012, 7, 2064-2073
64. 3 adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways Pharmacol. Res. 2008, 57, 303-311
65. 1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity J. Med. Chem. 2012, 55, 8075-8090
66. 2A adenosine receptors are required for ligand recognition Mol. Pharmacol. 1996, 49, 683-691
67. 2 adenosine receptors Naunyn-Schmeideberg's Arch. Pharamacol. 1993, 347, 521-526
68. Tosh, D. K.; Phan, K.; Gao, Z. G.; Gakh, A.; Xu, F.; Deflorian, F.; Abagyan, R.; Stevens, R. C.; Jacobson, K. A.; Katritch, V. Optimization of adenosine 5′-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment-based searching J. Med. Chem. 2012, 55, 4297-4308
69. Abagyan, R. A.; Orry, A.; Raush, E.; Budagyan, L.; Totrov, M. ICM Manual, 3.0; MolSoft LLC: La Jolla, CA, 2011.
70. 3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics; Borea, P. A., Ed.; Springer Science+Business Media B.V.: Dordrecht, Germany, 2010; pp 3-26.
71. 3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. J. Physiol. Biochem. [Online early access]. DOI: 10.1007/s13105-012-0222-7. Published Online: Nov 27, 2012.
72. Canny, S. A.; Cruz, Y.; Southern, M. A.; Griffin, P. R. PubChem promiscuity: a Web resource for gathering compound promiscuity data from PubChem Bioinformatics 2012, 28, 140-141
73. 3 adenosine receptor modulators: pharmacological activities and therapeutic implications J. Med. Chem. 2012, 55, 5676-5703
74. 3-selective adenosine agonists J. Med. Chem. 1994, 37, 636-646
75. 3 adenosine receptor J. Med. Chem. 2006, 49, 273-281
76. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Melman, N.; Tiwari, K. N.; Secrist, J. A.; Schneller, S. W.; Cristalli, G.; Johnson, C. R.; IJzerman, A. P. Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors J. Med. Chem. 1995, 38, 1174-1188
77. 3 receptor can explain their different biological behavior J. Mol. Graphics Modell. 2003, 21, 253-262
78. 3 receptor J. Med. Chem. 1999, 42, 1393-1400
79. Marquez, V. E. In Modified Nucleosides: In Biochemistry, Biotechnology, and Medicine; Herdewijn, P., Ed.; Wiley-VCH: Weinheim, Germany, 2008; Chapter 12, pp 307-341.
80. 3 receptor ligands Med. Chem. 2007, 15, 5440-5447
81. 3 receptor J. Med. Chem. 2009, 52, 7897-7900
82. 9-tetrahydrocannabinol treatment in rhesus monkeys J. Pharmacol. Exp. Ther. 2012, 342, 843-849
83. 1 receptor antagonists Bioorg. Med. Chem. 2012, 20, 5254-5261
84. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-1071
85. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
86. Zhang, C.; Srinivasan, Y.; Arlow, D. H.; Fung, J. J.; Palmer, D.; Zheng, Y.; Green, H. F.; Pandey, A.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Coughlin, S. R.; Kobilka, B. K. High-resolution crystal structure of human protease-activated receptor 1 Nature 2012, 492, 387-392
87. 12 nucleotide receptor J. Comput.-Aided Mol. Des. 2011, 25, 329-338
88. Jacobson, K. A.; Boeynaems, J. M. P2Y nucleotide receptors: promise of therapeutic applications Drug Discovery Today 2010, 15, 570-578
89. 1 receptors Circulation 2008, 118, 754-763
90. 1 knocked out mice J. Physiol. 2012, 590, 1943-1956
91. 2 receptor and design of a selective agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate J. Med. Chem. 2007, 50, 1166-1176
92. 4 receptor J. Med. Chem. 2011, 54, 4018-4033
93. 2A receptor antagonists PLoS One 2011, 6, e16088
94. Ferré, S.; Baler, R.; Bouvier, M.; Caron, M. G.; Devi, L. A.; Durroux, T.; Fuxe, K.; George, S. R.; Javitch, J. A.; Lohse, M. J.; Mackie, K.; Milligan, G.; Pfleger, K. D.; Pin, J. P.; Volkow, N. D.; Waldhoer, M.; Woods, A. S.; Franco, R. Building a new conceptual framework for receptor heteromers Nat. Chem. Biol. 2009, 5, 131-134
95. 2 receptor J. Neurochem. 2012, 123, 373-384
96. 2A adenosine receptor homodimer Bioorg. Med. Chem. Lett. 2008, 18, 4312-4315
97. 3 adenosine receptor binding assays using flow cytometry Biochem. Pharmacol. 2012, 83, 1552-1561
98. 2A adenosine receptor: application to a fluorescence polarization-based receptor binding assay Biochem. Pharmacol. 2010, 80, 506-511
99. Jacobson, K. A. GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs? Trends Pharmacol. Sci. 2010, 31, 575-579
100. Kecskés, A.; Tosh, D. K.; Wei, Q.; Gao, Z. G.; Jacobson, K. A. GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists Bioconjugate Chem. 2011, 22, 1115-1127
101. 3 adenosine receptor to improve post-ischemic/ reperfusion functions in isolated mouse hearts BMC Pharmacol. 2011, 11, 11
102. 2A adenosine receptor agonists J. Nanobiotechnol. 2010, 8, 11
103. Jayasekara, P. S.; Phan, K.; Tosh, D. K.; Kumar, T. S.; Moss, S. M.; Zhang, G.; Barchi, J. J.; Gao, Z. G.; Jacobson, K. A. Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles. Purinergic Signalling [Online early access]. DOI: 10.1007/s11302-012-9338-z. Published Online: Nov 20, 2012.
104. Stemmer, S. M.; Benjaminov, O.; Medalia, G.; Ciuraru, N. B.; Silverman, M. H.; Bar-Yehuda, S.; Fishman, S.; Harpaz, Z.; Farbstein, M.; Cohen, S.; Patoka, R.; Singer, B.; Kerns, W. D.; Fishman, P. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study Oncologist 2013, 18, 25-26
105. 3 adenosine receptor activation FASEB J. 2012, 26, 1855-1865
106. 3 adenosine receptors reduces mouse intraocular pressure Invest. Ophthalmol. Visual Sci. 2002, 43, 3021-3026
107. 1 receptor agonist J. Med. Chem. 2012, 55, 7623-7635
108. 6 receptor-induced secretion in MIN6 mouse pancreatic β cells Biochem. Pharmacol. 2013, 85, 991-998
109. 6 receptors Biochem. Biophys. Res. Commun. 2008, 370, 499-503
110. 13 receptor Purinergic Signalling 2013, 9, 67-79
111. Xu, J.; Morinaga, H.; Oh, D.; Li, P.; Chen, A.; Talukdar, S.; Lazarowski, E. R.; Olefsky, J. M.; Kim, J. J. GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity J. Immunol. 2012, 189, 1992-1999
112. 2 receptor Biochem. Pharmacol. 2011, 82, 1126-1133
113. 2 receptors activate neuroprotective mechanisms in astrocytic cells J. Neurochem. 2004, 91, 1471-4159
114. 4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise Am. J. Physiol.: Heart Circ. Physiol. 2012, 303, H835-H843
115. 6-receptor agonist upon introduction of a boranophosphate moiety Bioorg. Med. Chem. 2012, 20, 5483-5495
116. 6 receptors is a novel mediator of microglial phagocytosis Nature 2007, 446, 1091-1095
117. 14 and other P2Y receptors in degranulation of human LAD2 mast cells Purinergic Signalling 2013, 9, 31-40
118. 14 receptor agonists: truncation of the hexose moiety of uridine-5′-diphosphoglucose and its replacement with alkyl and aryl groups J. Med. Chem. 2010, 53, 471-480
119. Sesma, J. I.; Kreda, S. M.; Okada, S. F.; van Heusden, C.; Moussa, L.; Jones, L. C.; O'Neal, W. K.; Togawa, N.; Hiasa, M.; Moriyama, Y.; Lazarowski, E. R. The vesicular nucleotide transporter (VNUT) regulates the nucleotide content in airway epithelial mucin granules. Am. J. Physiol.: Cell Physiol. [Online early access]. Published Online: Mar 6, 2013.
120. 2 receptor agonist activity of nucleotide 5′-phosphonate analogues Bioorg. Med. Chem. 2012, 20, 2304-2315
121. 6 receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5′-triphosphate γ-ester modifications J. Med. Chem. 2010, 53, 4488-4501
122. Han, Y.; Moreira, I. S.; Urizar, E.; Weinstein, H.; Javitch, J. A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation Nat. Chem. Biol. 2009, 5, 688-695
123. 12 receptor J. Thromb. Haemostasis 2008, 6, 1908-1914
124. 2A receptor antagonist SYN115 in cocaine dependent individuals J. Addict. Res. Ther. 2012, March 28, Suppl. 1) 009
125. 3 adenosine receptor Biochem. Pharmacol. 2013, 85, 1171-1181
126. 2A adenosine receptor ACS Med. Chem. Lett. 2012, 3, 715-720
127. 1 antagonists with improved aqueous solubility. Bioorg. Med. Chem. Lett. [Online early access]. DOI: 10.1016/j.bmcl.2013.03.125. Published Online: Apr 6, 2013.